RayKnowChina Research Map
Shortlist0

GuilinGuilin Medical University

Affiliated Hospital of Guilin Medical University

桂林医学院附属医院

Listed for 12 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Affiliated Hospital of Guilin Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌35 papers led
  2. Hepatocellular carcinoma肝细胞癌66 papers led1 open trial led
  3. Chordoma脊索瘤1 paper led
  4. Osteosarcoma骨肉瘤3 papers led
  5. Neuroblastoma神经母细胞瘤3 papers led
  6. Ewing sarcoma尤文肉瘤0 papers led
  7. Multiple myeloma多发性骨髓瘤3 papers led1 open trial led
  8. Beta thalassaemiaβ 地中海贫血3 papers led
  9. Hepatic echinococcosis肝包虫病2 papers led
  10. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  11. Behçet disease白塞病0 papers led
  12. IgA nephropathyIgA 肾病1 paper led

Not listed for: Oesophageal squamous cell carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Gastrointestinal stromal tumour, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 35 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 1.5%.

Papers led
35
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 7720212022: 6620222023: 6620232024: 8820242025: 772025

2 hospitals in Guilin for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
    Phase
    Phase 1/Phase 2
    Started
    2025-11
    Registry
    NCT07258979

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Jiangmen, Kunming, Nanchang, Nanning, Shanghai, Shaoguan, Xiamen

  2. Recruiting
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    Phase
    N/A
    Started
    2023-06
    Registry
    NCT05892354

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical University; 13 listed hospitals as study sitesFuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Liuzhou, Nanchang, Nanning, Wuzhou

  3. Recruiting
    Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05527470

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuilin, Wuzhou

  4. Recruiting
    Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2022-12
    Registry
    NCT05717790

    Age 18 years to 70 years (registered criteria)

    Led by Fourth Affiliated Hospital of Guangxi Medical University; 6 listed hospitals as study sitesGuangzhou, Guilin, Liuzhou, Wuzhou, Zhongshan

  5. Not yet recruiting
    Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07064902

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesGuangzhou, Guilin, Xiamen

  6. Not yet recruiting
    Impacted Tooth Management and Osteoradionecrosis Risk in NPC
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07764887

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical University; 6 listed hospitals as study sitesGuilin, Liuzhou, Nanning, Wuzhou, Zhongshan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrent / metastatic diseaseRadiotherapy techniqueInduction / concurrent chemotherapy
Departments in papersRadiation oncologyENT / head & neck surgeryRadiology / nuclear medicineMedical oncology
Papers it led35
  1. Rhamnocitrin induces apoptosis of human nasopharyngeal carcinoma by inhibiting IGF-1R signaling pathway in vitro.2026Journal of Asian natural products research
  2. Integrative analysis of taurine metabolism-related genes prognostic signature with immunotherapy and identification of ABCB1 and GORASP1 as key genes in nasopharyngeal carcinoma.2025Amino acidsFree full text
  3. YTHDF2 enhances proliferation and metastasis of nasopharyngeal carcinoma by mediating m6A modification in destabilizing FOXO1 mRNA.2025Cancer biology & therapyFree full text
  4. Efficacy and Safety of Vascular-Targeting Agents Plus Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients: A Multicenter Clinical Cohort Study.2025Cancer control : journal of the Moffitt Cancer CenterFree full text
  5. Influence of COVID-19 Vaccination on Treatment-Related Adverse Events and Oncologic Outcomes of Nonmetastatic Nasopharyngeal Carcinoma.2025Head & neck
  6. Combined application of BNLF2b antibody with VCA-IgA, Rta-IgG, and Zta-IgA in nasopharyngeal carcinoma screening in the Guangxi region.2025PloS oneFree full text
  7. Anlotinib monotherapy in recurrent or metastatic nasopharyngeal carcinoma: a multicenter case-series analysis.2025Radiology and oncologyFree full text
  8. Interrogating ABCC1 and CASP1 as key players in epigallocatechin gallate's action against radiotherapy-resistant nasopharyngeal carcinoma.2025Scientific reportsFree full text
  9. Multi-Omics Exploration of the Mechanism of Curcumol to Reduce Invasion and Metastasis of Nasopharyngeal Carcinoma by Inhibiting NCL/EBNA1-Mediated UBE2C Upregulation.2024BiomoleculesFree full text
  10. Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma.2024Current molecular pharmacology
  11. Chemotherapy, Radiation Therapy, and Nasopharyngeal Carcinoma-Reply.2024JAMA oncology
  12. Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial.2024JAMA oncologyRCTFree full text
  13. An individualized immune prognostic signature in nasopharyngeal carcinoma.2024Oral oncology
  14. Development and validation of an individualized angiogenesis and tumor-infiltrating lymphocytes prognostic signature in nasopharyngeal carcinoma.2024Pathology, research and practice
  15. 18F-NaF uptake in skull-base bone as a predictor of treatment response in advanced nasopharyngeal carcinoma.2024Scientific reportsFree full text
  16. Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma : A prospective multicenter phase II trial.2024Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]RCT
  17. Building Practical Risk Prediction Models for Nasopharyngeal Carcinoma Screening with Patient Graph Analysis and Machine Learning.2023Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  18. Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.2023Frontiers in immunologyFree full text
  19. Clinical Significance of Serum Iron Metabolism-Related Markers in Patients with Nasopharyngeal Carcinoma.2023ORL; journal for oto-rhino-laryngology and its related specialties
  20. RNA-binding domain 2 of nucleolin is important for the autophagy induction of curcumol in nasopharyngeal carcinoma cells.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  21. Aloe-emodin targets multiple signaling pathways by blocking ubiquitin-mediated degradation of DUSP1 in nasopharyngeal carcinoma cells.2023Phytotherapy research : PTR
  22. Hypofractionated radiotherapy compared with conventionally fractionated radiotherapy to treat initial distant metastases in nasopharyngeal carcinoma: A multicenter, prospective, randomized, phase II trial.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
  23. MFSD4A inhibits the malignant progression of nasopharyngeal carcinoma by targeting EPHA2.2022Cell death & diseaseFree full text
  24. In silico analysis and experimental validation to exhibit anti-nasopharyngeal carcinoma effects of plumbagin, an anti-cancer compound.2022Journal of the science of food and agriculture
  25. Pathogenesis and Diagnostic Significance of EBV-miR-BARTs in Nasopharyngeal Carcinoma.2022Oxidative medicine and cellular longevityFree full text
  26. Study on the biological mechanism of urolithin a on nasopharyngeal carcinoma in vitro.2022Pharmaceutical biologyFree full text
  27. Pentagalloylglucose suppresses the growth and migration of human nasopharyngeal cancer cells via the GSK3β/β-catenin pathway in vitro and in vivo.2022Phytomedicine : international journal of phytotherapy and phytopharmacology
  28. Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.2022Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  29. Curcumol inhibits EBV-positive Nasopharyngeal carcinoma migration and invasion by targeting nucleolin.2021Biochemical pharmacology
  30. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.2021Cancer
  31. Methylation-associated silencing of miR-9-1 promotes nasopharyngeal carcinoma progression and glycolysis via HK2.2021Cancer scienceFree full text
  32. Exosomes in nasopharyngeal carcinoma.2021Clinica chimica acta; international journal of clinical chemistry
  33. Optimization, Characterization and in vivo Evaluation of Paclitaxel-Loaded Folate-Conjugated Superparamagnetic Iron Oxide Nanoparticles.2021International journal of nanomedicineFree full text
  34. Impact of the weekday of the first intensity-modulated radiotherapy treatment on the survival outcomes of patients with nasopharyngeal carcinoma: A multicenter cohort study.2021Oral oncology
  35. Curcumol simultaneously induces both apoptosis and autophagy in human nasopharyngeal carcinoma cells.2021Phytotherapy research : PTR
All its trials on ClinicalTrials.gov, any status13
  1. Maintenance Treatment of Apatinib in Nasopharyngeal CarcinomaStatus unknownNCT03130270Lead sponsorPhase 2Start 2017-01
  2. Impacted Tooth Management and Osteoradionecrosis Risk in NPCNot yet recruitingNCT07764887Study siteN/AStart 2026-08
  3. Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT07064902Study sitePhase 2Start 2026-08
  4. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.RecruitingNCT07258979Study sitePhase 1/Phase 2Start 2025-11
  5. Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After ChemoradiotherapyRecruitingNCT05892354Study siteN/AStart 2023-06
  6. Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal CarcinomaRecruitingNCT05717790Study siteN/AStart 2022-12
  7. Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaRecruitingNCT05527470Study sitePhase 3Start 2022-11
  8. Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal CarcinomaStatus unknownNCT05097209Study sitePhase 2Start 2022-04
  9. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  10. Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaCompletedNCT04350190Study sitePhase 2Start 2021-01
  11. Demethylated Drug in the Treatment of Nasopharyngeal CarcinomaStatus unknownNCT03701451Study sitePhase 1/Phase 2Start 2018-02
  12. Adjuvant Treatment of Apatinib in Nasopharyngeal CarcinomaStatus unknownNCT03612219Study sitePhase 2Start 2018-07
  13. ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following RadiotherapyTerminatedNCT02874651Study sitePhase 2Start 2016-10
More papers found outside PubMed (not counted)5
  1. Adjuvant apatinib following concurrent chemoradiotherapy in high-risk nasopharyngeal carcinoma: A multicenter, prospective, phase 2 study.2025Journal of Clinical Oncologyarticle
  2. An Integrated Analysis of RNA Sequencing and Molecular Docking Reveal EIF2AK2, IFIT1, and STAT1 as Key Targets of EGCG in Nasopharyngeal Carcinoma2025Research Squarepreprint
  3. Hypofractionated radiotherapy compared with conventionally fractionated radiotherapy to treat initial distant metastases in nasopharyngeal carcinoma: A multicenter, prospective, randomized, phase II trial.2023Journal of Clinical Oncologyconference-abstract
  4. Icariside II targets in vitro MAPK and PI3K/Akt signaling in human nasopharyngeal carcinoma cells to induce apoptotic death and suppress proliferation2023Research Squarepreprint
  5. Abstract 5128: Identification and characterization of nasopharyngeal carcinoma prognostic subtypes based on a circRNA classifier: Implications of stratified treatment2022Cancer Researchconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 66 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
66
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 101020212022: 111120222023: 111120232024: 151520242025: 18182025

1 hospital in Guilin for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT07141056

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Guilin Medical University; 1 listed hospital as study siteGuilin, Zhanjiang

  2. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiology / nuclear medicinePathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led66
  1. Bimetallic Nanozyme Amplifier for Synergistic Ferroptosis-Cuproptosis and Metabolic Reprogramming to Reshape Immunosuppressive Tumor Microenvironment.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Development of a nomogram for predicting microvascular invasion in patients with hepatocellular carcinoma.2025BMC cancerFree full text
  3. Exploring SLC25A42 as a Radiogenomic Marker from the Perioperative Stage to Chemotherapy in Hepatitis-Related Hepatocellular Carcinoma.2025Cancer biotherapy & radiopharmaceuticals
  4. USP7-DDX5-FASN axis drives fatty acid metabolism and supports hepatocellular carcinoma progression.2025Cellular signalling
  5. Diagnostic performance of LR-5 based on hypointensity on Gd-EOB-DTPA-enhanced MRI in the hepatobiliary phase for sHCC using LI-RADS v2018 criteria.2025Clinical radiology
  6. The PLANES model for unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus lenvatinib and PD-1 inhibitors: a multicenter, retrospective study.2025Frontiers in immunologyFree full text
  7. Case Report: Successful immune checkpoint inhibitor rechallenge after sintilimab-induced Guillain-Barré syndrome.2025Frontiers in immunologyFree full text
  8. Integrated multi-omics analysis and machine learning refine molecular subtypes and clinical outcome for hepatocellular carcinoma.2025HereditasFree full text
  9. NDUFAB1 promotes hepatocellular carcinoma progression by disrupting mitochondrial homeostasis and mitophagy pathway.2025International immunopharmacology
  10. Dihydroartemisinin alleviates diethylnitrosamine-induced hepatocarcinogenesis by targeting a novel MAZ/TRIM50 axis.2025International immunopharmacology
  11. MOF-Mediated Aloe-Emodin Delivery Enhances Hepatocellular Carcinoma Immunotherapy via Pyroptosis and Immunosuppressant Synergy.2025International journal of nanomedicineFree full text
  12. Hypericin Nanoparticles-Associated Photodynamic Therapy Modulates the Biological Behavior of Hepatocellular Carcinoma by SERPINE1.2025International journal of nanomedicineFree full text
  13. Casein kinase 1 family member CSNK1E can regulate proliferation and migration in hepatocellular carcinoma.2025Journal of cancer research and clinical oncologyFree full text
  14. MAZ-mediated N6-methyladenosine modification of ZEB1 promotes hepatocellular carcinoma progression by regulating METTL3.2025Journal of translational medicineFree full text
  15. Alterations of Nutrient Elements in Hepatocellular Carcinoma Patients Treated with Atezolizumab-Bevacizumab.2025Nutrition and cancer
  16. Novel Strategies against Hepatocellular Carcinoma through Lipid Metabolism.2025Oncology researchFree full text
  17. A clinical study exploring the prediction of microvascular invasion in hepatocellular carcinoma through the use of combined enhanced CT and MRI radiomics.2025PloS oneFree full text
  18. EXOSC3 knockdown induces G1/S phase arrest to suppress hepatocellular carcinoma cell proliferation.2025Scientific reportsFree full text
  19. Bioinformatics identification of shared signaling pathways and core targets linking Benzo[a]pyrene exposure to HCC progression.2025Toxicology
  20. Identification and validation of methylation-CpG prognostic signature for prognosis of hepatocellular carcinoma.2024AgingFree full text
  21. SNRPB promotes the progression of hepatocellular carcinoma via regulating cell cycle, oxidative stress, and ferroptosis.2024AgingFree full text
  22. Radiomics model based on contrast-enhanced computed tomography imaging for early recurrence monitoring after radical resection of AFP-negative hepatocellular carcinoma.2024BMC cancerFree full text
  23. Methylation-regulated tumor suppressor gene PDE7B promotes HCC invasion and metastasis through the PI3K/AKT signaling pathway.2024BMC cancerFree full text
  24. Deciphering the immunological and prognostic features of hepatocellular carcinoma through ADP-ribosylation-related genes analysis and identify potential therapeutic target ARFIP2.2024Cellular signalling
  25. The Combination of Gd-EOB-DTPA Enhanced T1 Mapping with Apparent Diffusion Coefficient could Improve the Diagnostic Efficacy of Hepatocellular Carcinoma Grading.2024Current medical imaging
  26. Role of Ubiquitin-specific Proteases in Hepatocellular Carcinoma Pathogenesis.2024Current topics in medicinal chemistry
  27. A Novel lncRNA lncRNA-4045 Promotes the Progression of Hepatocellular Carcinoma by Affecting the Expression of AKR1B10.2024Digestive diseases and sciences
  28. GCF2 mediates nicotine-induced cancer stemness and progression in hepatocellular carcinoma.2024Ecotoxicology and environmental safety
  29. Case report: Complete response after transcatheter arterial chemoembolization combined with donafenib plus tislelizumab therapy for hepatocellular carcinoma with main trunk portal vein tumor thrombus in a patient coinfected with HIV and HBV2024Frontiers in immunologyFree full text
  30. REXO2 up-regulation is positively correlated with poor prognosis and tumor immune infiltration in hepatocellular carcinoma.2024International immunopharmacology
  31. Iron-Based Nanoplatforms Achieve Hepatocellular Carcinoma Regression Through a Cascade of Effects.2024International journal of nanomedicineFree full text
  32. Hepatic infarction occurred after 125I particle stent treatment for hepatocellular carcinoma with portal vein tumor thrombus: A case report.2024Journal of cancer research and clinical oncologyFree full text
  33. A Network Meta-analysis of the Efficacy of Drug Therapy in First-line Treatment of Advanced Hepatocellular Carcinoma.2024Journal of gastrointestinal and liver diseases : JGLD
  34. The long-term efficacy and safety of apatinib are inferior to sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.2024MedicineFree full text
  35. ZBTB34 is a hepatocellular carcinoma-associated protein with a monopartite nuclear localization signal.2023AgingFree full text
  36. Integrated network findings reveal ubiquitin-specific protease 44 overexpression suppresses tumorigenicity of liver cancer.2023AgingFree full text
  37. Prognostic Significance of ZP3 in Hepatocellular Carcinoma.2023Combinatorial chemistry & high throughput screening
  38. Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study.2023Frontiers in immunologyFree full text
  39. Equilibrative nucleoside transporter 3 promotes the progression of hepatocellular carcinoma by regulating the AKT/mTOR signaling pathway.2023International journal of biological macromolecules
  40. Aberrant expression of cuproptosis‑related gene LIPT1 is associated with metabolic dysregulation of fatty acid and prognosis in hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  41. Pulmonary interleukin 1 beta/serum amyloid A3 axis promotes lung metastasis of hepatocellular carcinoma by facilitating the pre-metastatic niche formation.2023Journal of experimental & clinical cancer research : CRFree full text
  42. The mechanism of LSM2 in the progression of live hepatocellular carcinoma was analyzed based on bioinformatics.2023Medical oncology (Northwood, London, England)
  43. Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study.2023Radiology and oncologyRCTFree full text
  44. Nomogram for predicting severe abdominal pain after initial conventional transarterial chemoembolisation for hepatocellular carcinoma: a retrospective study.2023Scientific reportsFree full text
  45. Radiomics model based on contrast-enhanced computed tomography to predict early recurrence in patients with hepatocellular carcinoma after radical resection.2023World journal of gastroenterologyFree full text
  46. Clinical Significance of TUBGCP4 Expression in Hepatocellular Carcinoma.2022Analytical cellular pathology (Amsterdam)Free full text
  47. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.2022BMC cancerFree full text
  48. S1PR1 induces metabolic reprogramming of ceramide in vascular endothelial cells, affecting hepatocellular carcinoma angiogenesis and progression.2022Cell death & diseaseFree full text
  49. Exosomal miR-628-5p from M1 polarized macrophages hinders m6A modification of circFUT8 to suppress hepatocellular carcinoma progression.2022Cellular & molecular biology lettersFree full text
  50. Anti-hepatoma Effect of DC2.4 Cells Transfected with Tumor-Associated Antigen Cdc25C In Vitro.2022Current medical science
  51. G Protein-Coupled Receptor Kinase 4 Is a Novel Prognostic Factor in Hepatocellular Carcinoma.2022Disease markersFree full text
  52. Hepatocyte-targeting and tumor microenvironment-responsive liposomes for enhanced anti-hepatocarcinoma efficacy.2022Drug deliveryFree full text
  53. Hypoxia-induced LncRNA DACT3-AS1 upregulates PKM2 to promote metastasis in hepatocellular carcinoma through the HDAC2/FOXA3 pathway.2022Experimental & molecular medicineFree full text
  54. hsa-miR-9-5p-Mediated TSPAN9 Downregulation Is Positively Related to Both Poor Hepatocellular Carcinoma Prognosis and the Tumor Immune Infiltration.2022Journal of immunology researchFree full text
  55. Circ_0036412 affects the proliferation and cell cycle of hepatocellular carcinoma via hedgehog signaling pathway.2022Journal of translational medicineFree full text
  56. Preoperative contrast-enhanced computed tomography-based radiomics model for overall survival prediction in hepatocellular carcinoma.2022World journal of gastroenterologyRCTFree full text
  57. Clinical characterization and therapeutic targets of vitamin A in patients with hepatocholangiocarcinoma and coronavirus disease.2021AgingFree full text
  58. Predictive potential of Nomogram based on GMWG for patients with hepatocellular carcinoma after radical resection.2021BMC cancerFree full text
  59. AGLR is a novel index for the prognosis of hepatocellular carcinoma patients: a retrospective study.2021BMC surgeryRCTFree full text
  60. RNA sequencing identifies two novel liver-specific long noncoding RNAs with potential diagnostic value in hepatocellular carcinoma.2021Biomarkers in medicine
  61. A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma.2021Clinics and research in hepatology and gastroenterology
  62. CircRNA profiling identifies circRNF180 as a tumor suppressor in hepatocellular carcinoma.2021Epigenomics
  63. Lnc-ATG9B-4 aggravates progress of hepatocellular carcinoma through cell proliferation and migration by upregulating CDK5.2021Experimental biology and medicine (Maywood, N.J.)Free full text
  64. Exosomes synergized with PIONs@E6 enhance their immunity against hepatocellular carcinoma via promoting M1 macrophages polarization.2021International immunopharmacology
  65. Deciphering the effects of PYCR1 on cell function and its associated mechanism in hepatocellular carcinoma.2021International journal of biological sciencesFree full text
  66. Anti-hepatitis B virus activity and hepatoprotective effect of des(rhamnosyl) verbascoside from Lindernia ruellioides in vitro.2021Phytotherapy research : PTR
Chinese-language papers (not in the count)2
  1. [VIPR1 promoter methylation promotes transcription factor AP-2α binding to inhibit VIPR1 expression and promote hepatocellular carcinoma cell growth in vitro].2022Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  2. [miR-152 inhibits the epithelial-mesenchymal transition and renin-angiotensin system of human hepatocellular carcinoma cells by down-regulating AGTR1].2022Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
All its trials on ClinicalTrials.gov, any status3
  1. The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort StudyRecruitingNCT07141056Lead sponsorStart 2025-01
  2. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  3. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownNCT03236636Study sitePhase 3Start 2017-09

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Guilin for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Guilin for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgeryGastroenterology / hepatologyMedical oncology
Papers it led3
  1. Cracking the code: Deciphering the role of the tumor microenvironment in osteosarcoma metastasis.2023International immunopharmacology
  2. Anti-neoplastic characteristics and potential targets of calycosin against bisphenol A-related osteosarcoma: bioinformatics analysis.2021Bioengineered
  3. microRNA-377-3p inhibits osteosarcoma progression by targeting CUL1 and regulating Wnt/β-catenin signaling pathway.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Chinese-language papers (not in the count)1
  1. [Atypical extraosseous Ewing's sarcoma of sinonasal cranial base: a case report].2024Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
Earlier papers (2016–2020)2
  1. Expression and significance of Annexin A3 in the osteosarcoma cell lines HOS and U2OS.2019Molecular medicine reports
  2. Celastrol increases osteosarcoma cell lysis by γδ T cells through up-regulation of death receptors.2016Oncotarget

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 3 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 0020232024: 0020242025: 002025

1 hospital in Guilin for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Guilin for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery
Chinese-language papers (not in the count)1
  1. [Atypical extraosseous Ewing's sarcoma of sinonasal cranial base: a case report].2024Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

1 hospital in Guilin for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    CD38 Targeted -PET/ CT for Multiple Myeloma
    Phase
    N/A
    Started
    2026-07
    Registry
    NCT07782944

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Guilin Medical UniversityGuilin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & risk
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 3 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 1.0%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

2 hospitals in Guilin for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led 2 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 1.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Guilin for hepatic echinococcosis49 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Guilin for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

1 hospital in Guilin for Behçet disease149 hospitals in China for Behçet disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    Phase
    Phase 3
    Started
    2023-11
    Registry
    NCT06145893

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseRecruitingNCT06145893Study sitePhase 3Start 2023-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Guilin for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led1
  1. Impact of crescents on the immunosuppression treatment of IgA nephropathy.2025Renal failure
Chinese-language papers (not in the count)1
  1. Characteristics of disease distribution for the 1 370 renal biopsy cases in two hospitals from Guilin and Jining.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
All its trials on ClinicalTrials.gov, any status2
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  2. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

桂林医学院附属医院

Affiliated Hospital of Guilin Medical University

桂林

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Guilin Medical University; Second Affiliated Hospital of Guilin Medical University; Guilin Medical University Affiliated Hospital; Affiliated Hospital of Guilin Medical College; First Affiliated Hospital of Guilin Medical University; College of International Education of Guilin Medical University

Suggest a correctionDownload the data